A scientific clinical trial to study the effect of medicine namely Tranexamic Acid versus normal saline in reducing blood loss during brain surgery among patients diagnosed with brain tumours.

Effect of Tranexamic acid on the reduction of blood loss in Neuro Oncosurgical patients A Randomized control study - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/066769

Enrollment

Registered

2024-05-03

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Using Tranexamic acid in study group to study the reduction in blood loss in patients with supratentorial brain tumour undergoing Craniotomy and decompression: Injection Tranexamic acid

Eligibility

Inclusion criteria

Inclusion criteria: All patients aged 18-65 years with the diagnosis of a Supratentorial brain tumour planned for undergoing Craniotomy and decompression are to be recruited

Exclusion criteria

Exclusion criteria: 1. Allergy to tranexamic acid 2. Known Arterial or venous Thromboembolism 3. Known Coagulopathy- Altered PT, INR, aPTT 4. Use of Antiplatelet therapy or antocoagulant therapy 5. Significant Kidney (CKD 3-5) or Liver Disease (Child Pugh B, C). 6. Pregnant and Lactating Mothers 7. Patient Refusal to participate

Design outcomes

Primary

Measure	Time frame
Reduction in Blood LossTimepoint: 1. Blood loss during surgery is measured by the anaestheiologist . 2. Post operative hemoglobin and hematocrit will be measured on post operative day 2 and 5	—

Secondary

Measure	Time frame
1. Inraoperative surgical site assessment and Surgeons satisfaction. 2. Reduction in blood transfusion 3. Development of Deep vein ThrombosisTimepoint: 1. Intraoperative surgical site assessment, surgeons satisfaction and documentation of Boezaart score. 2.PT,INR will be measured on Post operative day 1. 3. Preoperative and post opeartive day 5 and 30 for Deep Vein Thrombosis screening will be done. 4. The indication, quantity and time of blood transfusion will be documented	—

Measure

Time frame

1. Inraoperative surgical site assessment and Surgeons satisfaction. 2. Reduction in blood transfusion 3. Development of Deep vein ThrombosisTimepoint: 1. Intraoperative surgical site assessment, surgeons satisfaction and documentation of Boezaart score. 2.PT,INR will be measured on Post operative day 1. 3. Preoperative and post opeartive day 5 and 30 for Deep Vein Thrombosis screening will be done. 4. The indication, quantity and time of blood transfusion will be documented

—

Countries

India

Contacts

Public ContactM Asiel Christopher

Basavatarakam IndoAmerican Cancer Hospital and Research Institute

capsjan@gmail.com9442212993

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026